Licia Grazzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/734446/publications.pdf

Version: 2024-02-01

232 papers 5,623 citations

38 h-index 60 g-index

236 all docs

236 docs citations

times ranked

236

3350 citing authors

#	Article	IF	Citations
1	Verapamil in the prophylaxis of episodic cluster headache: A double-blind study versus placebo. Neurology, 2000, 54, 1382-1385.	1.1	223
2	Noninvasive vagus nerve stimulation as acute therapy for migraine. Neurology, 2018, 91, e364-e373.	1.1	186
3	Behavioral and Pharmacologic Treatment of Transformed Migraine With Analgesic Overuse: Outcome at 3 Years. Headache, 2002, 42, 483-490.	3.9	164
4	The Migraine Disability Assessment (MIDAS) Questionnaire: Translation and Reliability of the Italian Version. Cephalalgia, 2001, 21, 947-952.	3.9	145
5	Increased familial risk of cluster headache. Neurology, 2001, 56, 1233-1236.	1.1	123
6	Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. Journal of Headache and Pain, 2015, 16, 61.	6.0	121
7	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. Journal of Headache and Pain, 2019, 20, 92.	6.0	116
8	Acute Treatment of Migraine Attacks: Efficacy and Safety of A Nonsteroidal Anti-Inflammatory Drug, Diclofenac-Potassium, in Comparison To Oral Sumatriptan and Placebo. Cephalalgia, 1999, 19, 232-240.	3.9	106
9	Topiramate in Cluster Headache Prophylaxis: an Open Trial. Cephalalgia, 2003, 23, 1001-1002.	3.9	95
10	Cervicogenic headache: a critical review of the current diagnostic criteria. Pain, 1998, 78, 1-5.	4.2	84
11	Biofeedback-assisted relaxation training for young adolescents with tension-type headache: a controlled study. Cephalalgia, 1998, 18, 463-467.	3.9	84
12	Two New SUNCT Cases Responsive to Lamotrigine. Cephalalgia, 2000, 20, 845-847.	3.9	80
13	Erenumab in the prevention of highâ€frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective realâ€life study. Headache, 2021, 61, 363-372.	3.9	75
14	Pain Processing in Medication Overuse Headache: A Functional Magnetic Resonance Imaging (fMRI) Study. Pain Medicine, 2012, 13, 255-262.	1.9	74
15	Quality of life and disability in primary chronic daily headaches. Neurological Sciences, 2003, 24, s97-s100.	1.9	71
16	Disability and quality of life in different primary headaches: results from Italian studies. Neurological Sciences, 2004, 25, s105-s107.	1.9	68
17	Chronic Migraine With Medication Overuse Pre–Post Withdrawal of Symptomatic Medication: Clinical Results and fMRI Correlations. Headache, 2010, 50, 998-1004.	3.9	68
18	Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up. Journal of Headache and Pain, 2017, 18, 15.	6.0	66

#	Article	IF	CITATIONS
19	Health-Related Quality of Life in Patients with Cluster Headache During Active Periods. Cephalalgia, 2002, 22, 818-821.	3.9	63
20	Longâ€term (48Âweeks) effectiveness, safety, and tolerability of erenumab in the prevention of highâ€frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache, 2021, 61, 1351-1363.	3.9	62
21	An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. Journal of Headache and Pain, 2019, 20, 26.	6.0	61
22	Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke?. Cephalalgia, 1998, 18, 618-621.	3.9	59
23	In Medicationâ€Overuse Headache, <scp>fMRI</scp> Shows Longâ€Lasting Dysfunction in Midbrain Areas. Headache, 2012, 52, 1520-1534.	3.9	58
24	Increased Plasma Nitrites in Migraine and Cluster Headache Patients in Interictal Period: Basal Hyperactivity of L-Arginine-No Pathway?. Cephalalgia, 2002, 22, 33-36.	3.9	57
25	Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. Journal of Headache and Pain, 2016, 17, 91.	6.0	57
26	Disability Pattern in Chronic Migraine With Medication Overuse: A Comparison With Migraine Without Aura. Headache, 2005, 45, 553-560.	3.9	50
27	Mindfulness and headache: A "new―old treatment, with new findings. Cephalalgia, 2016, 36, 1192-1205.	3.9	49
28	Abnormal 24-hour urinary excretory pattern of 6-sulphatoxymelatonin in both phases of cluster headache. Cephalalgia, 1998, 18, 664-667.	3.9	48
29	Homocysteine plasma levels in patients with migraine with aura. Neurological Sciences, 2008, 29, 173-175.	1.9	48
30	Disability in Chronic Migraine Patients With Medication Overuse: Treatment Effects at 1‥ear Followâ€up. Headache, 2004, 44, 678-683.	3.9	45
31	Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurological Sciences, 2005, 26, s162-s166.	1.9	45
32	Disability in chronic migraine with medication overuse: Treatment effects through 5 years. Cephalalgia, 2010, 30, 610-614.	3.9	45
33	Electromyographic Biofeedback-Assisted Relaxation Training in Juvenile Episodic Tension-Type Headache: Clinical Outcome at Three-Year Follow-Up the in of and for on with at is an as by. Cephalalgia, 2001, 21, 798-803.	3.9	43
34	I stay at home with headache. A survey to investigate how the lockdown for COVID-19 impacted on headache in Italian children. Cephalalgia, 2020, 40, 1459-1473.	3.9	43
35	A therapeutic alternative for tension headache in children: Treatment and 1-year follow-up results. Biofeedback and Self-regulation, 1990, 15, 1-6.	0.2	42
36	In-patient vs. day-hospital withdrawal treatment for chronic migraine with medication overuse and disability assessment: results at one-year follow-up. Neurological Sciences, 2008, 29, 161-163.	1.9	41

#	Article	IF	Citations
37	Flunarizine in Migraine: A Minireview. Headache, 1991, 31, 388-391.	3.9	40
38	Coexistence of Migraine and Cluster Headache: Report of 10 Cases and Possible Pathogenetic Implications. Headache, 1997, 37, 21-25.	3.9	39
39	The serotonergic agent <i>m</i> -chlorophenylpiperazine induces migraine attacks: A controlled study. Neurology, 2000, 55, 136-139.	1.1	39
40	Treatment of chronic migraine with medication overuse: is drug withdrawal crucial?. Neurological Sciences, 2009, 30, 85-88.	1.9	38
41	Neuroimaging in chronic migraine. Neurological Sciences, 2010, 31, 19-22.	1.9	38
42	Predictors of 12â€Months Relapse After Withdrawal Treatment in Hospitalized Patients With Chronic Migraine Associated With Medication Overuse: A Longitudinal Observational Study. Headache, 2017, 57, 60-70.	3.9	38
43	Microembolic Air Load During Contrastâ€Transcranial Doppler: A Trigger for Migraine With Aura?. Headache, 2010, 50, 1320-1327.	3.9	36
44	Behavioral Approaches for Primary Headaches: Recent Advances. Headache, 2018, 58, 913-925.	3.9	36
45	Multimorbidity in patients with chronic migraine and medication overuse headache. Acta Neurologica Scandinavica, 2018, 138, 515-522.	2.1	36
46	Global Burden of Headache Disorders in Children and Adolescents 2007–2017. International Journal of Environmental Research and Public Health, 2021, 18, 250.	2.6	36
47	Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study. Neurological Sciences, 2017, 38, 197-199.	1.9	35
48	Gingkolide B as migraine preventive treatment in young age: results at 1-year follow-up. Neurological Sciences, 2011, 32, 197-199.	1.9	34
49	Chronic migraine with medication overuse: Association between disability and quality of life measures, and impact of disease on patients' lives. Journal of the Neurological Sciences, 2015, 348, 60-66.	0.6	34
50	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 101.	6.0	34
51	Behavioral medicine for migraine and medication overuse headache. Current Pain and Headache Reports, 2009, 13, 241-248.	2.9	33
52	Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience. Neurological Sciences, 2015, 36, 33-35.	1.9	32
53	Disability in Chronic Migraine With Medication Overuse: Treatment Effects at 3 Years. Headache, 2007, 47, 1277-1281.	3.9	31
54	Magnesium as a preventive treatment for paediatric episodic tension-type headache: results at 1-year follow-up. Neurological Sciences, 2007, 28, 148-150.	1.9	31

#	Article	IF	CITATIONS
55	5-HT1A Receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test. NeuroReport, 1998, 9, 2605-2608.	1.2	30
56	Use of the Migraine Disability Assessment Questionnaire in Children and Adolescents With Headache: An Italian Pilot Study. Headache, 2003, 43, 767-773.	3.9	30
57	Pharmacological treatment compared to behavioural treatment for juvenile tension-type headache: results at two-year follow-up. Neurological Sciences, 2007, 28, S235-S238.	1.9	30
58	Disability in chronic daily headache: state of the art and future directions. Neurological Sciences, 2011, 32, 71-76.	1.9	30
59	Almotriptan 12.5 mg in menstrually related migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia, 2011, 31, 144-151.	3.9	30
60	Disability, Quality of Life, and Socioeconomic Burden of Cluster Headache: A Critical Review of Current Evidence and Future Perspectives. Headache, 2020, 60, 809-818.	3.9	30
61	Brief neurologist-administered behavioral treatment of pediatric episodic tension-type headache. Neurology, 2003, 60, 1215-1216.	1.1	29
62	No efficacy of transcranial direct current stimulation on chronic migraine with medication overuse: A double blind, randomised clinical trial. Cephalalgia, 2020, 40, 1202-1211.	3.9	29
63	Difficulties in work activities and the pervasive effect over disability in patients with episodic and chronic migraine. Neurological Sciences, 2015, 36, 9-11.	1.9	28
64	Transdermal Clonidine in the Prophylaxis of Episodic Cluster Headache: An Open Study. Headache, 1997, 37, 559-560.	3.9	27
65	alpha-Dihydroergocryptine in the Prophylaxis of Migraine: A Multicenter Double-Blind Study Versus Flunarizine. Headache, 1999, 39, 426-431.	3.9	27
66	Non-pharmacological approaches to treating chronic migraine with medication overuse. Neurological Sciences, 2009, 30, 89-93.	1.9	27
67	Are Depressive Symptomatology, Selfâ€Efficacy, and Perceived Social Support Related to Disability and Quality of Life in Patients With Chronic Migraine Associated to Medication Overuse? Data From a Crossâ€Sectional Study. Headache, 2015, 55, 636-645.	3.9	27
68	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. Journal of Headache and Pain, 2017, 18, 66.	6.0	27
69	The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patientâ€derived data. European Journal of Neurology, 2020, 27, 62.	3.3	27
70	Non-Pharmacological Approaches to Headaches: Non-Invasive Neuromodulation, Nutraceuticals, and Behavioral Approaches. International Journal of Environmental Research and Public Health, 2021, 18, 1503.	2.6	27
71	When should "chronic migraine―patients be considered "refractory―to pharmacological prophylaxis?. Neurological Sciences, 2008, 29, 55-58.	1.9	26
72	A prospective pilot study of the effect on catecholamines of mindfulness training vs pharmacological prophylaxis in patients with chronic migraine and medication overuse headache. Cephalalgia, 2019, 39, 655-664.	3.9	26

#	Article	lF	CITATIONS
73	Life with chronic pain during COVID-19 lockdown: the case of patients with small fibre neuropathy and chronic migraine. Neurological Sciences, 2021, 42, 389-397.	1.9	26
74	Orbitofrontal Dysfunction and Medication Overuse in Patients With <scp>M</scp> igraine. Headache, 2012, 52, 1511-1519.	3.9	25
75	Headache, eating and sleeping behaviors and lifestyle factors in preadolescents and adolescents: preliminary results from an Italian population study. Neurological Sciences, 2012, 33, 87-90.	1.9	25
76	Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse. Quality of Life Research, 2014, 23, 1273-1277.	3.1	25
77	Neurobrucellosis Mimicking Multiple Sclerosis: A Case Report. European Neurology, 1989, 29, 238-240.	1.4	24
78	The M-Chlorophenylpiperazine Test in Cluster Headache. Cephalalgia, 1997, 17, 666-672.	3.9	24
79	Disability and quality of life in headache: where we are now and where we are heading. Neurological Sciences, 2013, 34, 1-5.	1.9	24
80	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics, 2018, 18, 167-176.	2.8	24
81	ACT for migraine: effect of acceptance and commitment therapy (ACT) for high-frequency episodic migraine without aura: preliminary data of a phase-II, multicentric, randomized, open-label study. Neurological Sciences, 2019, 40, 191-192.	1.9	24
82	Functional-MRI evaluation of pain processing in chronic migraine with medication overuse. Neurological Sciences, 2009, 30, 71-74.	1,9	22
83	Restless legs syndrome is not associated with migraine with aura: a clinical study. Neurological Sciences, 2011, 32, 153-156.	1.9	22
84	Dependency-like behaviors and pain coping styles in subjects with chronic migraine and medication overuse: results from a 1-year follow-up study. BMC Neurology, 2014, 14, 181.	1.8	22
85	Trigeminal autonomic cephalgia with periorbital ecchymosis, ocular hemorrhage, hypertension and behavioral alterations. Pain, 2000, 88, 109-112.	4.2	21
86	Pharmacological behavioural treatment for children and adolescents with tension-type headache: preliminary data. Neurological Sciences, 2004, 25, s270-s271.	1,9	21
87	Cost of medication overuse headache in Italian patients at the time-point of withdrawal: a retrospective study based on real data. Neurological Sciences, 2017, 38, 3-6.	1.9	21
88	Non-pharmacological Approaches for Headaches in Young Age: An Updated Review. Frontiers in Neurology, 2018, 9, 1009.	2.4	21
89	Mindfulness meditation for chronic migraine in pediatric population: a pilot study. Neurological Sciences, 2018, 39, 111-113.	1.9	21
90	Medication-overuse headache: Description, treatment, and relapse prevention. Current Pain and Headache Reports, 2006, 10, 71-77.	2.9	20

#	Article	IF	Citations
91	An innovative approach for migraine prevention in young age: a preliminary study. Neurological Sciences, 2010, 31, 181-183.	1.9	20
92	Decision-making deficit in chronic migraine patients with medication overuse. Neurological Sciences, 2012, 33, 151-155.	1.9	19
93	Difficulties in work-related activities among migraineurs are scarcely collected: results from a literature review. Neurological Sciences, 2014, 35, 23-26.	1.9	19
94	Mindfulness and pharmacological prophylaxis have comparable effect on biomarkers of inflammation and clinical indexes in chronic migraine with medication overuse: results at 12Âmonths after withdrawal. Neurological Sciences, 2017, 38, 173-175.	1.9	19
95	Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire. Journal of Headache and Pain, 2018, 19, 85.	6.0	19
96	A Qualitative Study On Patients With Chronic Migraine With Medication Overuse Headache: Comparing Frequent And Nonâ€Frequent Relapsers. Headache, 2018, 58, 1373-1388.	3.9	19
97	Topiramate in migraine prophylaxis. Neurological Sciences, 2005, 26, s130-s133.	1.9	18
98	Psychological variables in chronic migraine with medication overuse before and after inpatient withdrawal: results at 1-year follow-up. Neurological Sciences, 2009, 30, 125-127.	1.9	18
99	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 98.	6.0	18
100	Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. Neurological Sciences, 2021, 42, 2637-2644.	1.9	18
101	Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation. Headache, 2021, 61, 895-905.	3.9	18
102	Mapping Assessments Instruments for Headache Disorders against the ICF Biopsychosocial Model of Health and Disability. International Journal of Environmental Research and Public Health, 2021, 18, 246.	2.6	18
103	Magnesium as a treatment for paediatric tension-type headache: a clinical replication series. Neurological Sciences, 2005, 25, 338-341.	1.9	17
104	Pain, Emotion, Headache. Headache, 2012, 52, 98-101.	3.9	17
105	Disability and mood state in patients with episodic and chronic migraine associated to medication overuse. Neurological Sciences, 2012, 33, 169-171.	1.9	17
106	Evaluation of immune parameters in chronic migraine with medication overuse. Neurological Sciences, 2014, 35, 171-173.	1.9	17
107	Onabotulinumtoxinâ€A in Chronic Migraine: Should Timing and Definition of Nonâ€Responder Status Be Revised? Suggestions From a Real‣ife Italian Multicenter Experience. Headache, 2019, 59, 1300-1309.	3.9	16
108	Effect of Biofeedback Treatment on Sympathetic Function in Common Migraine and Tension-Type Headache. Cephalalgia, 1993, 13, 197-200.	3.9	15

#	Article	IF	CITATIONS
109	Behavioral plus pharmacological treatment versus pharmacological treatment only for chronic migraine with medication overuse after day-hospital withdrawal. Neurological Sciences, 2009, 30, 117-119.	1.9	15
110	Italian Experience of Electromyographic-Biofeedback Treatment of Episodic Common Migraine: Preliminary Results. Headache, 1993, 33, 439-441.	3.9	14
111	Neuroendocrinology of cluster headache. Italian Journal of Neurological Sciences, 1999, 20, S18-S20.	0.1	14
112	The importance of anxiety and depression as factors in chronicization of primary headaches. Journal of Headache and Pain, 2000, 1, S45-S48.	6.0	14
113	Headache with medication overuse: treatment strategies and proposals of relapse prevention. Neurological Sciences, 2008, 29, 93-98.	1.9	14
114	Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. Neurological Sciences, 2010, 31, 115-119.	1.9	14
115	Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse. Neurological Sciences, 2014, 35, 37-39.	1.9	14
116	Biofeedback and behavioral treatments: filling some gaps. Neurological Sciences, 2014, 35, 121-127.	1.9	14
117	Psychosocial difficulties in patients with episodic migraine: a cross-sectional study. Neurological Sciences, 2016, 37, 1979-1986.	1.9	14
118	What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Review of Neurotherapeutics, 2020, 20, 1275-1286.	2.8	14
119	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The â€∞ImpACT-COVID-19 for Patients―Multi-Centre Observational Study. International Journal of Environmental Research and Public Health, 2021, 18, 340.	2.6	14
120	Narrative Medicine to integrate patients', caregivers' and clinicians' migraine experiences: the DRONE multicentre project. Neurological Sciences, 2021, 42, 5277-5288.	1.9	14
121	Role of nitric oxide in cluster headache. Italian Journal of Neurological Sciences, 1999, 20, S25-S27.	0.1	13
122	Therapeutic neurostimulation in chronic headaches: problems of patient selection. Neurological Sciences, 2008, 29, 59-61.	1.9	13
123	Non-pharmacological approaches in migraine prophylaxis: behavioral medicine. Neurological Sciences, 2010, 31, 133-135.	1.9	13
124	PO31. An observational study on chronic tension-type headache treatment with Quantum Molecular Resonance according to I.A.R.A. model®. Journal of Headache and Pain, 2015, 16, A176.	6.0	13
125	Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients. Current Pain and Headache Reports, 2018, 22, 71.	2.9	13
126	Facial pain in children and adolescents. Neurological Sciences, 2005, 26, s101-s103.	1.9	12

#	Article	IF	CITATIONS
127	The Reliability and Validity of the Visual Analog Mood Scales in Nonâ€Englishâ€Speaking Pain Patients. Pain Practice, 2012, 12, 626-632.	1.9	12
128	Pharmacotherapy for acute migraines in children and adolescents. Expert Opinion on Pharmacotherapy, 2019, 20, 455-463.	1.8	12
129	The Adaptation of Management of Chronic Migraine Patients With Medication Overuse to the Suspension of Treatment Protocols During the COVIDâ€19 Pandemic: Lessons From a Tertiary Headache Center in Milan, Italy. Headache, 2020, 60, 1463-1464.	3.9	12
130	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain and Therapy, 2021, 10, 637-650.	3.2	12
131	Cluster Headache Patients' Responses to Dexamethasone Suppression Test. Headache, 1988, 28, 130-132.	3.9	11
132	Chronic migraine with medication overuse: treatment outcome and disability at 3 years follow-up. Neurological Sciences, 2004, 25, s272-s273.	1.9	11
133	Reduction in the impact of chronic migraine with medication overuse after day-hospital withdrawal therapy. Neurological Sciences, 2008, 29, 176-178.	1.9	11
134	Headache frequency and symptoms of depression as predictors of disability in patients with idiopathic intracranial hypertension. Neurological Sciences, 2018, 39, 139-140.	1.9	11
135	The Impact of Primary Headaches on Patients' Lives: Italian Experience with the MIDAS and the SF-36 Questionnaires. Headache Care, 2004, 1, 123-128.	0.2	11
136	Psychological Assessment in Tension Headache Before and After Biofeedback Treatment. Headache, 1988, 28, 337-338.	3.9	10
137	Type II neurofibromatosis presenting as quadriceps atrophy. Italian Journal of Neurological Sciences, 1998, 19, 94-96.	0.1	10
138	Headaches and Arnold-Chiari Syndrome: When to Suspect and How to Investigate. Current Pain and Headache Reports, 2012, 16, 350-353.	2.9	10
139	Effectiveness of mindfulness by smartphone, for patients with chronic migraine and medication overuse during the Covid-19 emergency. Neurological Sciences, 2020, 41, 461-462.	1.9	10
140	Dihydroergokryptine Versus Dihydroergotamine in Migraine Prophylaxis: A Double-Blind Clinical Trial. Cephalalgia, 1991, 11, 117-121.	3.9	9
141	Sumatriptan in the Acute Treatment of Migraine Without Aura: Efficacy of 50-mg Dose. Headache, 1997, 37, 421-423.	3.9	9
142	Prevalence and characteristics of right-to-left shunt in migraine with aura: a survey on 120 Italian patients. Neurological Sciences, 2009, 30, 109-111.	1.9	9
143	Headache and Chiari malformation in young age: clinical aspects and differential diagnosis. Neurological Sciences, 2011, 32, 299-301.	1.9	9
144	Clinical and psychosocial features of frequent relapsers (FR) among patients with chronic migraine and medication overuse. Neurological Sciences, 2017, 38, 169-171.	1.9	9

#	Article	IF	CITATIONS
145	The use of MIDAS in patients with chronic migraine and medication-overuse headache: should we trust it?. Neurological Sciences, 2018, 39, 125-127.	1.9	9
146	Topiramate in the prevention of migraine: a review of its efficacy, tolerability, and acceptability. Neuropsychiatric Disease and Treatment, 2006, 2, 261-267.	2.2	9
147	A review of the treatment of primary headaches. Part I: Migraine. Italian Journal of Neurological Sciences, 1995, 16, 577-586.	0.1	8
148	Chronic headaches: pharmacological and non-pharmacological treatment. Neurological Sciences, 2007, 28, S134-S137.	1.9	8
149	Multidisciplinary approach to patients with chronic migraine and medication overuse: experience at the Besta Headache Center. Neurological Sciences, 2013, 34, 19-21.	1.9	8
150	Understanding the relationship between pain and emotion in idiopathic headaches. Neurological Sciences, 2013, 34, 29-31.	1.9	8
151	EHMTI-0036. Gammacore device for treatment of migraine attack: preliminary report. Journal of Headache and Pain, 2014, 15, .	6.0	8
152	Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment. Neurological Sciences, 2017, 38, 141-143.	1.9	8
153	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. Pain and Therapy, 2021, 10, 1605-1618.	3.2	8
154	Internal Ophthalmoplegia in Complicated Migraine: A Case Report. Headache, 1987, 27, 489-490.	3.9	7
155	A review of the treatment of primary headaches. Part II: Tension-type headache. Italian Journal of Neurological Sciences, 1998, 19, 2-9.	0.1	7
156	Chronic daily headache: personality study by means of computerized MMPI-2. Journal of Headache and Pain, 2000, 1, S67-S70.	6.0	7
157	Strategies for the treatment of autonomic trigeminal cephalalgias. Neurological Sciences, 2004, 25, s167-s170.	1.9	7
158	Primary headaches in children and adolescents. Neurological Sciences, 2004, 25, s232-s233.	1.9	7
159	Migraine with aura from pathophysiology to treatment: therapeutic strategies. Neurological Sciences, 2005, 26, s104-s107.	1.9	7
160	Medication overuse headache (MOH): complication of migraine or secondary headache?. Neurological Sciences, 2012, 33, 27-28.	1.9	7
161	Onabotulinum toxin A for treatment of chronic migraine with medication overuse. Neurological Sciences, 2013, 34, 27-28.	1.9	7
162	Approaches to treatments of chronic migraine associated with medication overuse: a comparison between different intensity regimens. Neurological Sciences, 2015, 36, 5-8.	1.9	7

#	Article	IF	CITATIONS
163	Establishment of an Italian chronic migraine database: a multicenter pilot study. Neurological Sciences, 2018, 39, 933-937.	1.9	7
164	Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!. Headache, 2020, 60, 804-806.	3.9	7
165	Adaptation of the management of chronic migraine patients with medication overuse to the suspension of treatment protocols during the COVIDâ€19 pandemic: Lessons from a tertiary headache center in Milan—6â€month results. Headache, 2021, 61, 961-962.	3.9	7
166	Management of chronic migraine with medication overuse by web-based behavioral program during the COVID-19 emergency: results at 12Âmonths. Neurological Sciences, 2022, 43, 1583-1585.	1.9	7
167	Pharmacological and behavioral treatment of pediatric migraine and tension-type headache. Italian Journal of Neurological Sciences, 1998, 19, 59-64.	0.1	6
168	Disability in young patients suffering from primary headaches. Neurological Sciences, 2004, 25, s111-s112.	1.9	6
169	What future for treatment of chronic migraine with medication overuse?. Neurological Sciences, 2011, 32, 19-22.	1.9	6
170	A 14-month study of change in disability and mood state in patients with chronic migraine associated to medication overuse. Neurological Sciences, 2013, 34, 139-140.	1.9	6
171	Emerging Therapies for Chronic Migraine. Current Pain and Headache Reports, 2014, 18, 408.	2.9	6
172	Disability and quality of life in patients with different forms of migraine. Journal of Headache and Pain, 2015, 16, A4.	6.0	6
173	A Short Review of the Non-invasive Transcutaneous Pericranial Electrical Stimulation Techniques and their Application in Headache. Current Pain and Headache Reports, 2018, 22, 4.	2.9	6
174	OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience. Neurological Sciences, 2018, 39, 171-172.	1.9	6
175	Mindfulness as an add-on treatment for patients with chronic migraine and medication overuse: a preliminary analysis. Neurological Sciences, 2020, 41, 469-471.	1.9	6
176	HEADWORK Questionnaire: Why Do We Need a New Tool to Assess Workâ€Related Disability in Patients With Migraine?. Headache, 2020, 60, 497-504.	3.9	6
177	Withdrawal failure in patients with chronic migraine and medication overuse headache. Acta Neurologica Scandinavica, 2021, 144, 408-417.	2.1	6
178	Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A realâ€ife perspective from the Italian chROnic migraiNe (IRON) project. Headache, 2021, 61, 936-950.	3.9	6
179	Physical Effort-Induced Changes in Immune Parameters. International Journal of Neuroscience, 1993, 68, 133-140.	1.6	5
180	Internal Ophthalmoplegia Associated with Migraine Attacks. Cephalalgia, 1994, 14, 461-462.	3.9	5

#	Article	lF	CITATIONS
181	Disability and migraine: MIDAS. Journal of Headache and Pain, 2001, 2, s25-s27.	6.0	5
182	Behavioural treatments: rationale and overview of the most common therapeutic protocols. Neurological Sciences, 2007, 28, S67-S69.	1.9	5
183	Day-hospital withdrawal for chronic migraine with medication overuse: results at 3Âyears follow-up. Neurological Sciences, 2013, 34, 167-169.	1.9	5
184	Psychiatric screening for migraine patients. Neurological Sciences, 2013, 34, 61-66.	1.9	5
185	Disability, ICF biopsychosocial model and burden of migraine. Journal of Headache and Pain, 2015, 16, A2.	6.0	5
186	Role of neurostimulation in migraine. Neurological Sciences, 2015, 36, 121-123.	1.9	5
187	Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results and changes in catastrophising attitude. Preliminary data. Neurological Sciences, 2018, 39, 173-174.	1.9	5
188	Gender and education inequalities in the cost of medication-overuse headache. Neurological Sciences, 2018, 39, 117-119.	1.9	5
189	Lessons from lockdown â€" behavioural interventions in migraine. Nature Reviews Neurology, 2021, 17, 195-196.	10.1	5
190	Effect of a Mindfulness-Based Intervention for Chronic Migraine and High Frequency Episodic Migraine in Adolescents: A Pilot Single-Arm Open-Label Study. International Journal of Environmental Research and Public Health, 2021, 18, 11739.	2.6	5
191	Addressing the cost of chronic and episodic migraine and its main drivers: a short-term longitudinal analysis from a third-level Italian center. Neurological Sciences, 2022, 43, 5717-5724.	1.9	5
192	Transdermal Clonidine in the Prophylaxis of Episodic Cluster Headache. Cephalalgia, 1997, 17, 551-551.	3.9	4
193	Disability in migraine patients: Italian experience. Journal of Headache and Pain, 2001, 2, s29-s31.	6.0	4
194	Headache in children and adolescents: conventional and unconventional approaches to treatment. Neurological Sciences, 2004, 25, s223-s225.	1.9	4
195	The multimodal treatment in headaches. Journal of Headache and Pain, 2015, 16, A47.	6.0	4
196	Proposal of a model for multidisciplinary treatment program of chronic migraine with medication overuse: preliminary study. Neurological Sciences, 2015, 36, 169-171.	1.9	4
197	The evaluation of difficulties with work-related activities caused by migraine: towards a specific questionnaire. Neurological Sciences, 2018, 39, 131-133.	1.9	4
198	Value of treatment of headache patients and need to improve headache patients' journey. Neurological Sciences, 2018, 39, 115-116.	1.9	4

#	Article	IF	CITATIONS
199	Feasibility and effect of mindfulness approach by web for chronic migraine and high-frequency episodic migraine without aura at in adolescents during and after COVID emergency: preliminary findings. Neurological Sciences, 2022, 43, 5741-5744.	1.9	4
200	Role of Physical Training on Immune Function: Preliminary Data. International Journal of Neuroscience, 1990, 51, 249-252.	1.6	3
201	An Italian pilot study on the use of the migraine disability assessment questionnaire. Journal of Headache and Pain, 2000, 1, 47-51.	6.0	3
202	Treatment of chronic daily headache with medication overuse. Neurological Sciences, 2003, 24, s125-s127.	1.9	3
203	Selective vs. Complete Family Interview for Detecting those Affected by Familial Cluster Headache. Cephalalgia, 2004, 24, 938-939.	3.9	3
204	Measuring responses to therapy in headache patients: new and traditional end-points. Neurological Sciences, 2004, 25, s108-s110.	1.9	3
205	Behavioural approach to the "difficult―patient. Neurological Sciences, 2008, 29, 96-98.	1.9	3
206	Caliber Fluctuations of Cervical Internal Carotid Artery and Migraine With Aura: A Possible Vasospasm Detected by Ultrasonographic Examinations. Headache, 2009, 49, 1068-1072.	3.9	3
207	Headache in young age: classification of primary forms. Neurological Sciences, 2010, 31, 77-79.	1.9	3
208	Evolution of headache in a population of young Italian headache sufferers: a brief report. Neurological Sciences, 2011, 32, 193-195.	1.9	3
209	Atypical Facial and Head Pain in Childhood and Adolescence. Current Pain and Headache Reports, 2018, 22, 43.	2.9	3
210	Chronic migraine and medication overuse: which strategy for a complex scenario. Neurological Sciences, 2019, 40, 175-176.	1.9	3
211	Mindfulness and other behavioral approaches. Neurological Sciences, 2022, 43, 5745-5747.	1.9	3
212	Amelanotic leptomeningeal melanoblastosis. Case report. Italian Journal of Neurological Sciences, 1990, 11, 171-175.	0.1	2
213	Short and Medium-Term Influence of Physical Activity on Immune Parametersa. International Journal of Neuroscience, 1993, 71, 267-276.	1.6	2
214	Quality of life and illness behaviour in chronic daily headache patients. Journal of Headache and Pain, 2000, 1, S61-S65.	6.0	2
215	The serotonergic system in migraine. Journal of Headache and Pain, 2001, 2, s43-s46.	6.0	2
216	Chronic headache in young patients: clinical aspects and treatment suggestions. Neurological Sciences, 2003, 24, s112-s114.	1.9	2

#	Article	IF	Citations
217	Catastrophizing attitude changes after onabotulinumtoxin A treatment in chronic migraine. Neurological Sciences, 2019, 40, 201-202.	1.9	2
218	Deeper inside the Experience of Pediatric Headache: A Narrative Study. Journal of Behavioral and Brain Science, 2020, 10, 432-454.	0.5	2
219	Derangement of the Hypothalamo-Pituitary Axis (HPa) in Cluster Headache: Further Considerations. Cephalalgia, 1989, 9, 141-142.	3.9	1
220	Menstrual migraine. Journal of Headache and Pain, 2001, 2, s117-s119.	6.0	1
221	Chronic headaches: pharmacological and non-pharmacological treatment. Neurological Sciences, 2006, 27, s174-s178.	1.9	1
222	A proposal for a national registry on chronic migraines. Journal of Headache and Pain, 2015, 16, A40.	6.0	1
223	International Clinical Collaboration in Headache Medicine: The International Visiting Scholars Program. Headache, 2019, 59, 446-449.	3.9	1
224	The use of pharmacologic prophylaxis for migraine in pediatric and adolescent age: a crucial concern. Neurological Sciences, 2022, 43, 2121.	1.9	1
225	EMG-BFB Treatment and Sympathetic Indexes Changes in Common Migraine. Cephalalgia, 1991, 11, 141-142.	3.9	0
226	Immunological Study in Cluster Headache Cephalalgia, 1991, 11, 256-257.	3.9	0
227	MIDAS questionnaire modification for a new MIDAS junior questionnaire: a clinical experience at the Neurological Institute ?C. Besta?. Neurological Sciences, 2004, 25, s261-s262.	1.9	0
228	EHMTI-0037. Botulinum A toxin for treatment of chronic migraine. Journal of Headache and Pain, 2014, 15, .	6.0	0
229	Non invasive neurostimulation. Journal of Headache and Pain, 2015, 16, A18.	6.0	0
230	The importance of specific rehabilitation for an obese patient with idiopathic intracranial hypertension: a case report. International Journal of Rehabilitation Research, 2018, 41, 183-185.	1.3	0
231	Migraine and prophylaxis. Neurological Sciences, 2020, 41, 383-384.	1.9	0
232	Neuromodulation and Other Non-pharmacological Approaches in Tension-Type Headache. Headache, 2020, , 157-172.	0.4	0